Treatment of Cushing's disease: A mechanistic update

Journal of Endocrinology

Volumn 223, Issue 2, 2014, Pages R19-R39

  Cuevas Ramos, Daniel ^a,b   Fleseriu, Maria ^c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

ACTH; Cabergoline; cortisol; Cushing's disease; Ketoconazole; LCI699; Mifepristone; Pasireotide

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE ANTAGONIST; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE; CABERGOLINE; CORTICOSTEROID ANTAGONIST; CORTICOTROPIN; CYPROHEPTADINE; DESMOPRESSIN; DOPAMINE RECEPTOR STIMULATING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOMIDATE; FLUCONAZOLE; GLUCOCORTICOID ANTAGONIST; GLUCOCORTICOID RECEPTOR ANTAGONIST; HYDROCORTISONE; KETOCONAZOLE; LCI 699; LEUKEMIA INHIBITORY FACTOR; METYRAPONE; MICRORNA; MIFEPRISTONE; MITOTANE; PASIREOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOIC ACID; SOMATOSTATIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VALPROIC ACID; LIGAND; SOMATOSTATIN RECEPTOR; STEROID SYNTHESIS INHIBITOR;

ACNE; ACTH SECRETING CELL; ADRENAL INSUFFICIENCY; ATAXIA; CAPILLARY RESISTANCE; CARDIOVASCULAR DISEASE; CELL CYCLE REGULATION; CHOLESTASIS; CUSHING DISEASE; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HEPATITIS; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERPHAGIA; HYPERTENSION; HYPOKALEMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LETHARGY; LIVER TOXICITY; MINERALOCORTICOID HYPERTENSION; MOLECULAR BIOLOGY; NAUSEA; NONHUMAN; NOSE OBSTRUCTION; ORTHOSTATIC HYPOTENSION; RASH; REVIEW; SOMNOLENCE; WEIGHT GAIN; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; HYPOPHYSIS ADRENAL SYSTEM; METABOLISM; MOLECULARLY TARGETED THERAPY; PITUITARY ACTH HYPERSECRETION; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LIGANDS; MOLECULAR TARGETED THERAPY; PITUITARY ACTH HYPERSECRETION; PITUITARY-ADRENAL SYSTEM; RECEPTORS, SOMATOSTATIN; SIGNAL TRANSDUCTION; SOMATOSTATIN; STEROID SYNTHESIS INHIBITORS;

EID: 84915763457     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-14-0300     Document Type: Review

References (176)

1. Aghi MK 2008 Management of recurrent and refractory Cushing disease. Nature Clinical Practice. Endocrinology & Metabolism 4 560-568. (doi:10.1038/ncpendmet0947)
2. Alberti KG, Christensen NJ, Christensen SE, Hansen AP, Iversen J, Lundbaek K, Seyer-Hansen K & Orskov H 1973 Inhibition of insulin secretion by somatostatin. Lancet 2 1299-1301. (doi:10.1016/S0140-6736(73) 92873-0)
3. Alexandraki KI, Kaltsas GA, Ie Roux CW, Fassnacht M, Ajodha S, Christ- Crain M, Akker SA, Drake WM, Edwards R, Allolio B et al. 2010 Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clinical Endocrinology 72 305-311. (doi:10.1111/j.1365-2265.2009.03631.x)
4. Allolio B, Schulte HM, Kaulen D, Reincke M, Jaursch-Hancke C & Winkelmann W 1988 Nonhyponotic low-dose etomidate for rapid correction of hypercortisolemia in Cushing's syndrome. Klinische Wochenschrift 10 e37-e40. (doi:10.1007/BF01735795)
5. Amaral FC, Torres N, Saggioro F, Neder L, Machado HR, Silva WA Jr, Moreira AC & Castro M 2009 MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. Journal of Clinical Endocrinology and Metabolism 94 320-323. (doi:10.1210/jc.2008-1451)
6. Ambrosi B, Bochicchio D, Fadin C, Colombo P & Faglia G 1990 Failure of somatostatin and octreotide to acutely affect the hypothalamic- pituitary-adrenal function in patients with corticotropin hypersecretion. Journal of Endocrinological Investigation 13 257-261. (doi:10.1007/BF03349555)
7. Arnardottir S & Sigurjonsdottir HA 2011 The incidence and prevalence of Cushing's diseasemay be higher than previously though: results from a retrospective study in Iceland 1955 through 2009. Clinical Endocrinology 74 792-793. (doi:10.1111/j.1365-2265.2010.03961.x)
8. AssieG, Bahurel H, Coste J, Silvera S, KujasM,Dugué MA, Karray F,Dousset B, Bertherat J, Legmann P et al. 2007 Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's syndrome. Journal of Clinical Endocrinology and Metabolism 92 172-179. (doi:10.1210/jc.2006-1328)
9. Auernhammer CJ & Melmed S 2000 Leukemia-inhibitory factor- neuroimmune modulator of endocrine function. Endocrine Reviews 21 313-345. (doi:10.1210/edrv.21.3.0400)
10. Bamberger CM, Schulte HM & Chrousos GP 1996 Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocrine Reviews 17 245-261. (doi:10.1210/edrv-17-3-245)
11. Barbot M, Albiger N, Ceccato F, Zilio M, Frigo MZ, Denaro L, Mantero F & Scaroni C 2014 Combination therapy for Cushing's disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole? Pituitary 17 109-117. (doi:10.1007/s11102-013-0475-3)
12. Batista DL, Zhang X,Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA & Klibanski A 2006 The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pitutiary adenomas. Journal of Clinical Endocrinology and Metabolism 91 4482-4488. (doi:10.1210/jc.2006-1245)
13. Baudry C, Coste J, Bou Khalil R, Silvera S, Guignat L, Guibourdenche J, Abbas H, Legmann P, Bertagna X & Bertherat J 2012 Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. European Journal of Endocrinology 167 473-481. (doi:10.1530/EJE-12-0358)
14. Ben-Shlomo A, Schimd H, Wawrowsky K, Pichurin O, Hubina E, Chesnokova V, Liu NA, Culler M & Melmed S 2010 Differential ligandmediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. Journal of Clinical Endocrinology and Metabolism 94 4342-4350. (doi:10.1210/jc.2009-1311)
15. Bertagna X 1994 Proopiomelanocortin-derived peptides. Endocrinology and Metabolism Clinics of North America 23 467-485.
16. Bertagna X, Bertagna C, Luton JP,Husson JM & Girard F 1984 The newsteroid analog RU-486 inhibits glucocorticoid action in man. Journal of Clinical Endocrinology and Metabolism 59 25-28. (doi:10.1210/jcem-59-1-25)
17. Bertagna X, Bertagna C, Laudat MH, Husson JM, Girard F & Luton JP 1986 Pituitary-adrenal response to the antiglucocorticoid action of RU486 in Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 63 639-643. (doi:10.1210/jcem-63-3-639)
18. Bertagna X, Guignat L, Groussin L & Bertherat J 2006 Cushing disease. Best Practice & Research. Clinical Endocrinology & Metabolism 23 607-623. (doi:10.1016/j.beem.2009.06.001)
19. Bertagna X,PivonelloR, FleseriuM,ZhangY,RobinsonP,Taylor A,WatsonCE, Maldonado M, Hamrahian AH, Boscaro M et al. 2014 LCI699, a potent 11b-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. Journal of Clinical Endocrinology and Metabolism 99 1375-1383. (doi:10.1210/jc.2013-2117)
20. Berwaerts JJ, Verhelst JA, Verhaert GC, Verhaegen AA & Abs RE 1998 Corticotropin-dependent Cushing's syndrome in older people: presentation of five cases and therapeutical use of ketoconazole. Journal of the American Geriatrics Society 46 880-884.
21. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ et al. 2008 Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. Journal of Clinical Endocrinology and Metabolism 93 2454-2462. (doi:10.1210/jc.2007-2734)
22. Biller BM, Colao A, Petersenn S, Bonert V & Boscaro M 2010 Review: Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocrine Disorders 10 1-14. (doi:10.1186/1472-6823-10-10)
23. Bilodeau S, Vallette-Kasic S, Gauthier Y, Figarella-Branger D, Brue T, Berthelet F, Lacroix A, Batista D, Stratakis C, Hanson J et al. 2006 Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes and Development 20 2871-2886. (doi:10.1101/gad.1444606)
24. Bledsoe T, Island DP, Ney RL & Liddle GW 1964 An effect of o,p0-DDD on the extra-adrenal metabolism of cortisol in man. Journal of Clinical Endocrinology and Metabolism 24 1303-1311. (doi:10.1210/jcem-24-12-1303)
25. Bode H, Seiz M, Lammert A, Brockmann MA, Back W, Hammes HP & Thomé C 2010 SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Experimental and Clinical Endocrinology & Diabetes 118 760-763. (doi:10.1055/s-0030-1253419)
26. Boden G, Ryan IG, Eisenschmid BL, Shelmet JJ & Owen OE 1986 Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995. New England Journal of Medicine 314 1686-1689. (doi:10.1056/NEJM198606263142606)
27. Bolland MJ, Holdaway IM, Berkeley JE, Lim S, Dransfield WJ, Conaglen JV, Croxson MS, Gamble GD, Hunt PJ & Toomath RJ 2011 Mortality and morbidity in Cushing's syndrome in New Zeland. Clinical Endocrinology 75 436-442. (doi:10.1111/j.1365-2265.2011.04124.x)
28. Boscaro M, Barzon L, Fallo F & Sonino N 2001 Cushing's syndrome. Lancet 357 783-791. (doi:10.1016/S0140-6736(00)04172-6)
29. Boscaro M, Ludiam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J et al. 2009 Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. Journal of Clinical Endocrinology and Metabolism 94 115-122. (doi:10.1210/jc.2008-1008)
30. Brazeau P, Vale W, Burgus R, Ling N, Nutcher M, Rivier J & Guillemin R 1973 Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179 77-79. (doi:10.1126/science.179.4068.77)
31. de Bruin C, Feelders RA, Lamberts SW & Hofland LJ 2009 Somatostatin and dopamine receptors as targets for medical treatment of Cushing's syndrome. Reviews in Endocrine & Metabolic Disorders 10 91-102. (doi:10.1007/s11154-008-9082-4)
32. de Bruin C, Hofland LJ, Nieman LK, van Koetsveld PM, Waaijers AM, Sprij-Mooij DM, van Essen M, Lamberts SW, de Herder WW & Feelders RA 2012 Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion. Journal of Clinical Endocrinology and Metabolism 97 455-462. (doi:10.1210/jc.2011-1264)
33. Budry L, Balsalobre A, Gauthier Y, Khetchoumian K, L'Honore A, Vallette S, Brue T, Figarella-Branger D, Meij B & Drouin J 2012 The selector gene Pax7 dictates alternate pituitary cell fates through its pioneer action on chromatin remodeling. Genes and Development 26 2299-2310. (doi:10.1101/gad.200436.112)
34. Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Leftkowitz MP & Ménard J 2011 Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation 124 1945-1955. (doi:10.1161/CIRCULATIONAHA.111.029892)
35. Camacho AM, Cash R, Brough AJ & Wilroy RS 1967 Inhibition of adrenal steroidogenesis by amino-glutethimide and the mechanism of action. Journal of the American Medical Association 202 20-26. (doi:10.1001/jama.1967.03130140078010)
36. Castinetti F, Morange I, Jaquet P, Conte-Devoix B & Brue T 2008 Ketoconazole revisited: a preoperative or postoperartive treatment in Cushing disease. European Journal of Endocrinology 158 91-99. (doi:10.1530/EJE-07-0514)
37. Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, Do Cao C, Morange I, Picó A, Ouzounian S et al. 2009 Merits and pitfalls of mifepristone in Cushing's syndrome. European Journal of Endocrinology 160 1003-1010. (doi:10.1530/EJE-09-0098)
38. Castinetti F, Laurence G, PaulineG,MarieM, PeterK, DelphineD, Philippe C, Fiorina L, Bruno D, Vantyghem MC et al. 2014 Ketoconzaole in Cushing's disease: is it worth a try? Journal of Clinical Endocrinology and Metabolism 99 1623-1630. (doi:10.1210/jc.2013-3628)
39. Cavagnini F, Paneral AE, Valentini F, Bulgheroni P, Peracchi M & Pinto M 1975 Inhibition of ACTH response to oral and intravenous metyrapone by antiserotonergic treatment in man. Journal of Clinical Endocrinology and Metabolism 41 143-148. (doi:10.1210/jcem-41-1-143)
40. Cavagnini F, Invitti C & Polli EE 1984 Sodium valproate in Cushing disease (letter). Lancet 2 162. (doi:10.1016/S0140-6736(84)91074-2)
41. Chow JT, Thompson GB, Grant CS, Farley DR, Richards ML & Young WF Jr 2008 Bilateral laparoscopic adrenalectomy for corticotrophindependent Cushing's syndrome: a review of the Mayo Clinic experience. Clinical Endocrinology 68 513-519. (doi:10.1111/j.1365-2265.2007.03082.x)
42. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR & Feldman D 2001 Succesful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU486). Journal of Clinical Endocrinology and Metabolism 86 3568-3573. (doi:10.1210/jcem.86.8.7740)
43. Colao A, Pivonello R, Tripodi FS, Orio F Jr, FeroneD, CerboneG,Di Somma C, Merola B & Lombardi G 1997 Failure of long-term therapy with sodium valproate in Cushing's disease. Journal of Endocrinological Investigation 20 387-392. (doi:10.1007/BF03347989)
44. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR & Biller BM 2012 A 12-month phase 3 study of pasireotide in Cushing's disease. New England Journal of Medicine 366 914-924. (doi:10.1056/NEJMoa1105743)
45. Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J & Casanueva FF 2014 Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations. Pituitary 17 180-186. (doi:10.1007/s11102-013-0483-3)
46. Cueto C & Brown JHU 1958 Biological studies on an adrenocorticolytic agent and the isolation of the active components. Endocrinology 62 326-333. (doi:10.1210/endo-62-3-326)
47. Cuevas-Ramos D & Fleseriu M 2014 Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. Journal of Molecular Endocrinology 52 R223-R240. (doi:10.1530/JME-14-0011)
48. Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH & Romijn JA 2007 Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. Journal of Clinical Endocrinology and Metabolism 92 976-981. (doi:10.1210/jc.2006-2112)
49. Delgado V, Biermasz NR, van Thiel SW, Ewe SH, Marsan NA, Holman ER, Feelders RA, Smit JW, Bax JJ & Pereira AM 2012 Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clinical Endocrinology 77 99-105. (doi:10.1111/j.1365-2265.2011.04326.x)
50. Dewis DC, Bu'lock DE, Earnshaw R & Kelly WF 1983 Experience with trilostane in the treatment of Cushing's syndrome. Clinical Endocrinology 18 533-540. (doi:10.1111/j.1365-2265.1983.tb00590.x)
51. Dickstein G, Spindel A, Schechner C, Adawi F & Gutman H 1991 Spontaneous remission in Cushing's disease. Archives of Internal Medicine 151 185-189. (doi:10.1001/archinte.1991.00400010171028)
52. Dillard TH, Gultekin SH, Delashaw JB Jr, Yedinak CG, Neuwelt EA & Fleseriu M 2011 Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary 14 80-91. (doi:10.1007/s11102-010-0264-1)
53. Du L, Bergsneider M, Mirsadrael L, Young SH, Jonker JW, Downes M, Yong WH, Evans RM & Heaney AP 2013 Evidence for orphan nuclear receptor TR4 in the etiology of Cushing disease. PNAS 110 8555-8560. (doi:10.1073/pnas.1306182110)
54. Engelhardt D & Weber MM 1994 Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. Journal of Steroid Biochemistry and Molecular Biology 49 261-267. (doi:10.1016/0960-0760(94)90267-4)
55. Engelhardt D, Mann K, Hormann R, Braun S & Karl H 1983 Ketoconazole inhibits cortisol secretion of an adrenal adenoma in vivo and in vitro. Klinische Wochenschrift 61 373-375. (doi:10.1007/BF01485030)
56. Estrada J, Boronat M, Mielgo M, Magallón R, Millan I, Diez S, Lucas T & Barceló B 1997 The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. New England Journal of Medicine 336 172-177. (doi:10.1056/NEJM199701163360303)
57. Feelders RA & Hofland LJ 2013 Medical treatment of Cushing's disease. Journal of Clinical Endocrinology and Metabolism 98 425-438. (doi:10.1210/jc.2012-3126)
58. Feelders RA, de Bruin C & Pereira AM2010a Medical treatment of Cushing's disease with pasireotide mono or combination therapy with cabergoline and ketoconazole modulates somatostatin receptor subtype expression on corticotroph tumor cells [abstract OR14-6]. Endocrine Reviews 31(suppl 1) S845.
59. Feelders RA, Hofland LJ & de Herder WW 2010b Medical treatment of Cushing syndrome: adrenal-blocking drugs and ketoconazole. Neuroendocrinology 92(Suppl 1) 111-115. (doi:10.1159/000314292)
60. Feelders RA, de Bruin C, Pereira AM, Romjin JA, Netea-Maier RT, Hermus AR, Zelissen PM, van Heerebeek R, de Jong FH, van der Lely AJ et al. 2010c Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. New England Journal of Medicine 362 1846-1848. (doi:10.1056/NEJMc1000094)
61. Feelders RA, Pulgar SJ, Kempel A & PereiraAM2012 The burden of Cushing's disease (CD): clinical and health-related quality of life aspects. European Journal of Endocrinology 167 11-26. (doi:10.1530/EJE-11-1095)
62. Feldman D 1986 Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocrine Reviews 7 409-420. (doi:10.1210/edrv-7-4-409)
63. Fernando MA & Heaney AP 2005 a1-Adrenergic receptor antagonists: novel therapy for pituitary adenomas. Molecular Endocrinology 19 3085-3096. (doi:10.1210/me.2004-0471)
64. Ferone D, Pivonello C, Vitale G, Zatelli MC, Colao A & Pivonello R 2013 Molecular basis of pharmacological therapy in Cushing's disease. Endocrine 46 181-198. (doi:10.1007/s12020-013-0098-5)
65. Ferrari C, Bertazzoni A & Ghezzi M 1977 More on cyproheptadine (letter). New England Journal of Medicine 296 576-577. (doi:10.1056/NEJM197703102961022)
66. Fleseriu M 2012 Medical management of persistent and recurrent Cushing disease. Neurosurgery Clinics of North America 23 653-668. (doi:10.1016/j.nec.2012.06.012)
67. Fleseriu M & PetersennS 2012MedicalmanagementofCushing's disease:what is the future? Pituitary 15 330-341. (doi:10.1007/s11102-012-0397-5)
68. Fleseriu M & Petersenn S 2013 New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy. Journal of Neuro-Oncology 114 1-11. (doi:10.1007/s11060-013-1151-1)
69. Fleseriu M, Loriaux DL & Ludlam WH 2007 Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful. Current Opinion in Endocrinology, Diabetes, and Obesity 14 323-328. (doi:10.1097/MED.0b013e328248b498)
70. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C & SEISMIC Study investigators 2012 Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 97 2039-2049. (doi:10.1210/jc.2011-3350)
71. Fleseriu M, Pivonello R, Pedroncelli AM, Patino H, Ye M, Aout M & Feelders RA 2014 Study design of a phase II trial of subcutaneous pasireotide alone or combined with cabergoline in patients with Cushing's disease. Presented at The 96th Endocrine Society's Annual Meeting/16th International Congress of Endocrinology, Chicago, IL, USA. June 21-24, 2014. Poster Board MON-0715.
72. Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D & Melmed S 2011 EGFR as therapeutic target for human, canine, and mouse ACTH-secreting pitutiary adenomas. Journal of Clinical Investigation 121 4712-4721. (doi:10.1172/JCI60417)
73. Gatto F & Hofland LJ 2011 The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocrine-Related Cancer 18 R233-R251. (doi:10.1530/ERC-10-0334)
74. Godbout A,ManavelaM,Danilowicz K, Beauregard H, Bruno OD & Lacroix A 2010 Cabergoline monotherapy in the long-term treatment of Cushing's disease. European Journal of Endocrinology 163 709-716. (doi:10.1530/EJE-10-0382)
75. Gower DB 1974Modifiers of steroid-hormone metabolism: a review of their chemistry, biochemistry and clinical applications. Journal of Steroid Biochemistry 5 501-523. (doi:10.1016/0022-4731(74)90051-X)
76. Greenman Y 2010 Management of dyslipidemia in Cushing syndrome. Neuroendocrinology 92(Suppl 1) 91-95. (doi:10.1159/000314294)
77. He L & Hannon GJ 2004 MicroRNAs: small RNAs with a big role in gene regulation. Nature Reviews. Genetics 5 522-531. (doi:10.1038/nrg1379)
78. Heaney AP 2004 PPAR-g in Cushing's disease. Pituitary 7 265-269. (doi:10.1007/s11102-005-1430-8)
79. Heaney AP, Fernando M, Yong WH & Melmed S 2002 Functional PPAR-g receptor is a novel therapeutic target for ACTH-secreting pitutiary adenomas. Nature Medicine 8 1281-1287. (doi:10.1038/nm784)
80. Henry R, Mudaliar S, Hermosillo Reséndiz K, Ligueros-SaylanM, Chenji S & Golor G 2011 Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers. Endocrine Reviews 32 P3-P274. (doi:10.1210/er.2009-0043)
81. Hertz R, Pittman JA & Graff MM 1956 Amphenone: toxicity and effects on adrenal and thyroid function in man. Journal of Clinical Endocrinology and Metabolism 16 705-723. (doi:10.1210/jcem-16-6-705)
82. Heyn J, Greiger C & Hinske CL 2012 Medical suppression of hypercortisolemia in Cushing's syndrome with particular consideration of etomidate. Pituitary 15 117-125. (doi:10.1007/s11102-011-0314-3)
83. van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE et al. 2005 Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. American Journal of Physiology. Endocrinology and Metabolism 289 E278-E287. (doi:10.1152/ajpendo.00004.2005)
84. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de HerderWWet al. 2005 The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. European Journal of Endocrinology 152 645-654. (doi:10.1530/eje.1.01876)
85. Iino K, Oki Y, Yamashita M, Matsushita F, Hayashi C, Yogo K, Nishizawa S, Yamada S, MaekawaM, Sasano H et al. 2010 Possible relevance between prohormone convertase 2 expression and tumor growth in human adrenocorticotropin-producing pituitary adenoma. Journal of Clinical Endocrinology and Metabolism 95 4003-4011. (doi:10.1210/jc.2009-2716)
86. Jeffcoate WJ, Rees LH, Tomlin S, Jones AE, Edwards CR & Besser GM 1977 Metyrapone in long-term management of Cushing's disease. British Medical Journal 23 215-217.
87. Jimenez-Rema L, Leal-Cerro A, Garciá J,Garciá-Luna PP, Astorga R & BernalG 1989 In vitro effects of ketoconazole on corticotrope cell morphology and ACTH secretion of two pituitary adenomas recovered from patients with Nelson's syndrome. Acta Endocrinologica 121 185-190. (doi:10.1530/acta.0.1210185)
88. Johanssen S & Allolio B 2007 Mifepristone (RU486) in Cushing's syndrome. European Journal of Endocrinology 157 561-569. (doi:10.1530/EJE-07-0458)
89. Kamenicky P, Droumaguet C, Salenave S, Blanchard A, Jublanc C, Gautier JF, Brailly-Tabard S, Leboulleux S, Schlumberger M, Baudin E et al. 2011 Mitotane, metyrapone, and ketoconazol combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 96 2796-2804. (doi:10.1210/jc.2011-0536)
90. Karaca Z, Tanriverdi F & Unluhizarci K 2010 Pregnancy and pituitary disorders. European Journal of Endocrinology 162 453-475. (doi:10.1530/EJE-09-0923)
91. Koerker DJ, RuchW, Chideckel E, Palmer J, Goodner CJ, Ensinck J & Gale CC 1974 Somatostatin: hypothalamic inhibitor of the endocrine pancreas. Science 184 482-484. (doi:10.1126/science.184.4135.482)
92. Koppeschaar HP, Croughs RJ, Thijseeen JH & Schwarz F 1986 Response to neurotransmitter modulating drugs in patients with Cushing disease. Clinical Endocrinology 25 661-667. (doi:10.1111/j.1365-2265.1986.tb03621.x)
93. Kreutzer J, Jeske I, Hofmann B, Blumcke I, Fahlbusch R, Buchfelder M & Buslei R 2009 No effect of the PPAR-g agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo. Clinical Neuropathology 28 430-439.
94. Krieger DT, Amorosa L & Linick F 1975 Cyproheptadine-induced remission of Cushing's disease. New England Journal of Medicine 293 893-896. (doi:10.1056/NEJM197510302931802)
95. Kroiss M, Quinkler M, Lutz WK, Allolio B & Fassnacht M 2011 Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clinical Endocrinology 75 585-591. (doi:10.1111/j.1365-2265.2011.04214.x)
96. Labeur M, Paez-Pereda M & Arzt E 2009 Potential of retinoic acid derivatives for the treatment of corticotroph pitutiary adenomas. Reviews in Endocrine & Metabolic Disorders 10 103-109. (doi:10.1007/s11154-008-9080-6)
97. Lamberts SW & Birkehager JC 1976 Bromocriptine in Nelson's syndrome and Cushing's disease. Lancet 2 811. (doi:10.1016/S0140-6736(76) 90656-5)
98. Lamberts SW, Stefanko SZ, de Lange SA, Fermin H, van der Vijver JC, Weber RF & de Jong FH 1980 Failure of clinical remission after transsphenoidal removal of amicroadenoma in a patient with Cushing disease: multiple hyperplastic and adenomatous cell nets in surrounding pitutiary tissue. Journal of Clinical Endocrinology and Metabolism 50 793-795. (doi:10.1210/jcem-50-4-793)
99. Lamberts SW, de Lange SA & Stefanko SZ 1982 Adrenocorticotropinsecreting pitutiary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: diferentes in the regulation of hormone secretion. Journal of Clinical Endocrinology and Metabolism 54 286-291. (doi:10.1210/jcem-54-2-286)
100. Lamberts SW, Uitterlinden P & Klijn JM 1989a The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinologica 120 760-766. (doi:10.1530/acta.0.1200760)
101. Lamberts SW, Zuyderwijk J, den Holder F, van Koetsveld P & Hofland L 1989b Studies on the conditions determing the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. Neuroendocrinology 50 44-50. (doi:10.1159/000125200)
102. Leiba S, Weinstein R, Shindel B, Lapidot M, Stern E, Levavi H, Rusecki Y & Abramovici A 1989 The protracted effect of o,p0-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo. Annales d'Endocrinologie 50 49-53.
103. Liddle GW, Estep HL, Kendall JW, Williams WC Jr & Townes AW 1959 Clinical application of a new test of pituitary reserve. Journal of Clinical Endocrinology and Metabolism 19 875-894. (doi:10.1210/jcem-19-8-875)
104. Lila AR, Gopal RA, Acharya SV, George J, Sarathi V, Bandgar T,Menon PS & Shah NS 2010 Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocrine Practice 16 968-976. (doi:10.4158/EP10031.OR)
105. Lindsay JR, Jonklaas J, Oldfield EH & Nieman LK 2005 Cushing's syndrome during pregnancy: personal experience and review of the literature. Journal of Clinical Endocrinology and Metabolism 90 3077-3083. (doi:10.1210/jc.2004-2361)
106. Liu NA, Ben-Shlomo A & Melmed S 2011a Molecular biology of Cushing's disease. In Cushing's Disease, Endocrine Updates, vol 31, ch 2, pp. 19-32. Eds B Swearingen and BMK Biller. New York, NY, USA: Springer Science. (doi:10.1007/978-1-4614-0011-0_2)
107. Liu NA, Jiang H, Ben-Shlomo A, Wawrowsky K, Fan XM, Lin S & Melmed S 2011b Targeting zebrafish and murin pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. PNAS 108 8414-8419. (doi:10.1073/pnas.1018091108)
108. Loli P, Berselli ME & Tagliaferri M 1986 Use of ketoconazole in the treatment of Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 63 1365-1371. (doi:10.1210/jcem-63-6-1365)
109. Loose DS, Stover EP & Feldman D 1983 Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonism activity in cultured cells. Journal of Clinical Investigation 72 404-408. (doi:10.1172/JCI110982)
110. Luton JP, Mahoudeau JA, Bouchard P, Thieblot P, Hautecouverture M, Simon D, Laudat MH, Tourtou Y & Bricaire H 1979 Treatment of Cushing's disease by o,p0DDD. Survey of 62 cases. New England Journal of Medicine 300 459-464. (doi:10.1056/NEJM197903013000903)
111. Mannelli M, Cantini G, Poli G, Mangoni M, Nesi G, Canu L, Rapizzi E, Borgogni E, Ercolino T, Piccini V et al. 2010 Role of the PPAR-g system in normal and tumoral pituitary corticotropic cells and adrenal cells. Neuroendocrinology 92 23-27. (doi:10.1159/000314312)
112. Maraka GB & Stark E 1974 Effect of gamma amino-butyric acid (GABA) and GABA antagonist drugs on ACTH release. Neuroendocrinology 16 178-190. (doi:10.1159/000122564)
113. Melmed S 2003 Mechanisms for pituitary tumorigenesis: the plastic pitutiary. Journal of Clinical Investigation 112 1603-1618. (doi:10.1172/JCI20401)
114. Miller JW & Crapo L 1993 The medical treatment of Cushing's syndrome. Endocrine Reviews 14 443-458. (doi:10.1210/edrv-14-4-443)
115. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT & Klibanski A 1995 Somatostatin receptor subtype gene expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 80 1386-1392. (doi:10.1210/jcem.80.4.7714115)
116. Misbin RI, Canary J & Williard D 1976 Aminoglutethimide in the treatment of Cushing's syndrome. Journal of Clinical Pharmacology 16 645-651. (doi:10.1002/j.1552-4604.1976.tb01504.x)
117. Missale C, Nash SR, Robinson SW, Jaber M & Caron MG 1998 Dopamine receptors: from structure to function. Physiological Reviews 78 189-225.
118. Morcos M, Fohr B, Tafel J, Pfisterer F, Hamann A, Humpert P, Bode H, Schwenger V, Zeier M, Becker C et al. 2007 Long-term treatment of central Cuhsing's syndromewith rosiglitazone. Experimental and Clinical Endocrinology & Diabetes 115 292-297. (doi:10.1055/s-2007-970162)
119. Murray RD, Kim K, Ren SG, Lewis I, Weckbecker G, Bruns C & Melmed S 2004 The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. Journal of Clinical Endocrinology and Metabolism 89 3027-3032. (doi:10.1210/jc.2003-031319)
120. Nader N, Raverot G, Emptoz-Bonneton A, Déchaud H, Bonnay M, Baudin E & Pugeat M 2006 Mitotante has an estrogenic effect on sex hormonebinding globulin and corticosteroid-binding globulin in humans. Journal of Clinical Endocrinology and Metabolism 91 2165-2170. (doi:10.1210/jc.2005-2157)
121. Nelson AA & Woodard G 1949 Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachrorophenyl)- 1,1-dichlorethane (DDD or TDE). Archives of Pathology 48 387-394.
122. Newell-Price J, Bertagna X, Grossman AB & Nieman LK 2006 Cushing's syndrome. Lancet 367 1605-1617. (doi:10.1016/S0140-6736(06)68699-6)
123. Nieman LK 2002 Medical therapy for Cushing's disease. Pituitary 5 77-82. (doi:10.1023/A:1022308429992)
124. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, Merriam GR, Bardin CW & Loriaux DL 1985 Succesful treatment of Cushing's syndrome with the glucocorticoid antagonist RU-486. Journal of Clinical Endocrinology and Metabolism 61 536-540. (doi:10.1210/jcem-61-3-536)
125. Nissen SE & Wolski K 2010 Rosiglitazone revisited: an updated metaanalysis of risk for myocardial infarction and cardiovascular mortality. Archives of Internal Medicine 170 1191-1201. (doi:10.1001/archinternmed.2010.207)
126. Ortiz LD, Syro LV, Scheithauer BW, Ersen A, Uribe H, Fadul CE, Rotondo F, Horvath E & Kovacs K 2012 Anti-VEGF therapy in pitutiary carcinoma. Pituitary 15 445-449. (doi:10.1007/s11102-011-0346-8)
127. Park MS, Rosai J, Nguyen HT, Capodieci P, Cordon-Cardo C & Koff A 1999 p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. PNAS 96 6382-6387. (doi:10.1073/pnas.96.11.6382)
128. van der Pas R, Hofland L, Hofland J, Taylor AE, Arit W, Steenbergen J, van Koetsveld PM, de Herder WW, de Jong FH & Feelders RA 2012 Fluconazole inhibits human adrenocortical stereoidogenesis in vitro. Journal of Endocrinology 215 403-412. (doi:10.1530/JOE-12-0310)
129. van der Pas R, Feelders RA, Gatto F, de BruinC, Pereira AM,van Koetsveld PM, Sprij Mooij DM, Waaijers AM, Dogan F, Schulz S et al. 2013 Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists. Journal of Clinical Endocrinology and Metabolism 98 E1880-E1890. (doi:10.1210/jc.2013-1987)
130. Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO, Katznelson L & Laws ER Jr 2008 Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. Journal of Clinical Endocrinology and Metabolism 93 358-362. (doi:10.1210/jc.2007-2013)
131. Pecori Giraldi F, Ambrogio AG, Andrioli M, Sanguin F, Karamouzis I, Corsello SM, Scaroni C, Arvat E, Pontecorvi A & Cavagnini F 2012 Potential role for retinoic acid in patients with Cushing's disease. Journal of Clinical Endocrinology and Metabolism 97 3577-3583. (doi:10.1210/jc.2012-2328)
132. Pivonello R, Ferone D & de Herder WW 2004 Dopamine receptor expression and function in corticotroph pituitary tumors. Journal of Clinical Endocrinology and Metabolism 89 2452-2462. (doi:10.1210/jc.2003-030837)
133. Pivonello R, De Martino MC, Cappablanca P, De Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SW & Colao A 2009 The medical treatment of Cushing's disease: effectiveness of chronic treatment with dopamine agonist cabergoline in patients unsuccessfully treated by surgery. Journal of Clinical Endocrinology and Metabolism 94 223-230. (doi:10.1210/jc.2008-1533)
134. Plöckinger U, Hoffmann U, Geese M, Lupp A, Buchfelder M, Flitsch J, Vajkoczy P, JakobW,SaegerW,Schulz S et al.2012DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. European Journal of Endocrinology 166 223-234. (doi:10.1530/EJE-11-0737)
135. Plotsky PM, Otto S & Sutton S 1987 Neurotransmitter modulation of corticotropin releasing factor secretion into the hypophysial-portal circulation. Life Sciences 41 1311-1317. (doi:10.1016/0024-3205(87) 90211-6)
136. Pont A, Williams PL, Loose DS, Feldman D, Reitz RE, Bochra C & Stevens DA 1982 Ketoconazole blocks adrenal steroid synthesis. Annals of Internal Medicine 97 370. (doi:10.7326/0003-4819-97-3-370)
137. Potts GO, Creange JE, Harding HR & Schane HP 1978 Trilostane, an orally active inhibitor of steroid biosynthesis. Steroids 32 257-267. (doi:10.1016/0039-128X(78)90010-7)
138. Preda VA, Sen J, Karavitaki N & Grossman AB 2012 Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. European Journal of Endocrinology 167 137-143. (doi:10.1530/EJE-12-0746)
139. Qian ZR, Asa SL, Siomi H, Siomi MC, Yoshimoto K, Yamada S, Wang EL, Rahman MM, Inoue H, ItakuraMet al. 2009 Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Modern Pathology 22 431-441. (doi:10.1038/modpathol.2008.202)
140. Reincke M, Allolio B, Kaulen D, Jarusch-Hancke C & Winkleman W 1988 The effect of sodium valproate in Cushing's disease, Nelson's syndrome, and Addison's disease. Klinische Wochenschrift 66 686-689. (doi:10.1007/BF01726927)
141. Ren SG, Kim S, Taylor J, Dong J, Moreau JP, Culler MD & Melmed S 2003 Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. Journal of Clinical Endocrinology and Metabolism 88 5414-5421. (doi:10.1210/jc.2003-030302)
142. Rene P, Grino M, Viollet C, Videau C, Jullian E, Bucchini D, Epelbaum J, Bertagna X & de Keyzer Y 2002 Overexpression of the V3 vasopressin receptor in transgenic mice corticotropes leads to increased basal corticosterone. Journal of Neuroendocrinology 14 737-744. (doi:10.1046/j.1365-2826.2002.00834.x)
143. Richardson UI & Schonbrunn A 1981 Inhibition of adrenocorticotropin secretion by somatostatin in pituitary cells in culture. Endocrinology 108 281-290. (doi:10.1210/endo-108-1-281)
144. Riedl M, Maier C, Zettinig G, Nowotny P, Schima W & Luger A 2006 Long term control of hypercortisolism with fluconazole: case report and in vitro studies. European Journal of Endocrinology 154 519-524. (doi:10.1530/eje.1.02120)
145. Ritzel K, Beuschlein F, Mickisch A, Osswald A, Scbeider HJ, Schopohl J & ReinckeM2013 Clinical review: Outcome of bilateral adrenalectomy in Cushing's syndrome: a systematic review. Journal of Clinical Endocrinology and Metabolism 98 3939-3948. (doi:10.1210/jc.2013-1470)
146. Robinson BG, Hales IB, Henniker AJ, Ho K, Luttrell BM, Smee IR & Stiel JN 1987 The effect of o,p0-DDD on adrenal steroid replacement therapy requirements. Clinical Endocrinology 27 437-444. (doi:10.1111/j.1365-2265.1987.tb01171.x)
147. Rocheville M, Lange DC, Kumar U, Patel SC & Patel YC 2000 Receptors for dopamine and somatostatin formation of hetero-oligomers with enhanced functional activity. Science 288 154-157. (doi:10.1126/science.288.5463.154)
148. Schonbrunn A 1982 Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology 110 1147-1154. (doi:10.1210/endo-110-4-1147)
149. Schteingart DE, Tsao HS & Taylor CI 1980 Sustained remission of Cushing's disease with mitotane and pitutiary irradiation. Annals of Internal Medicine 92 613-619. (doi:10.7326/0003-4819-92-5-613)
150. Schulte HM, Benker G, Reinwein D, SippellWG & Allolio P 1990 Infusion of low dose etomidate: correction of hypercortislemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. Journal of Clinical Endocrinology and Metabolism 70 1426-1430. (doi:10.1210/jcem-70-5-1426)
151. Siler TM, Yen SC, Vale W & Guillemin R 1974 Inhibition by somatostatin on the release of TSH induced in man by thyrotropin-releasing factor. Journal of Clinical Endocrinology and Metabolism 38 742-745. (doi:10.1210/jcem-38-5-742)
152. Silva AP, Bethmann K, Raulf F & Schmid HA 2005 Regulation of ghrelin secretion by somatostatin analog in rats. European Journal of Endocrinology 152 887-894. (doi:10.1530/eje.1.01914)
153. Sonino N 1987 The use of ketoconazole as an inhibitor of steroid production. New England Journal of Medicine 317 812-818. (doi:10.1056/NEJM198709243171307)
154. Sonino N & Boscaro M 1999 Medical therapy for Cushing's disease. Endocrinology and Metabolism Clinics of North America 28 211-222. (doi:10.1016/S0889-8529(05)70064-5)
155. Sonino N, Boscaro M, Paoletta A, Mantero F & Ziliotto D 1991 Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clinical Endocrinology 35 347-352. (doi:10.1111/j.1365-2265.1991.tb03547.x)
156. Sonino N, Boscaro M, Fallo F & Fava G 1992 Potential therapeutic effects of ritanserin in Cushing's disease. Journal of the American Medical Association 267 1073. (doi:10.1001/jama.1992.03480080043020)
157. Southren AL, Weinsenfeld S, Laufer A & Goldner MG 1961 Effect of o,p0DDD in a patient with Cushing's síndrome. Journal of Clinical Endocrinology and Metabolism 21 201-208. (doi:10.1210/jcem-21-2-201)
158. Stalla GK, Brockmeier SJ, Renner U, Newton C, Buchfelder M, Stalla J & Müller OA 1994 Octreotide exerts different effects in vivo and in vitro in Cushing's disease. European Journal of Endocrinology 130 125-131. (doi:10.1530/eje.0.1300125)
159. Stenzel-Poore MP, Cameron VA, Vaughn J, Sawchenko PE & Vale W 1992 Development of Cushing's syndrome in corticotropin-releasing factor transgenicmice. Endocrinology 130 3378-3386. (doi:10.1210/endo.130.6.1597149)
160. Suda T, Tozawa F, Mouri T, Sasaki A, Shibasaki T, Demura H & Shizume K 1983 Effects of cyproheptadine, reserpine, and synthetic corticotroph releasing factor on pituitary glands from patients with Cushing's disease. Journal of Clinical Endocrinology and Metabolism 56 1094-1099. (doi:10.1210/jcem-56-6-1094)
161. Sugar AM, Alsip GA, Craven PC & Stevens DA 1987 Pharmacology and toxicity of high-dose ketoconazole. Antimicrobial Agents and Chemotherapy 31 1874-1878. (doi:10.1128/AAC.31.12.1874)
162. Suri D & Weiss RE 2005 Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. Journal of Clinical Endocrinology and Metabolism 90 1340-1346. (doi:10.1210/jc.2004-1746)
163. Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, Uribe H, Cusimano M, Kovacs K & Horvath E 2011 Treatment of pitutiary neoplasms with temozolomide: a review. Cancer 117 454-462. (doi:10.1002/cncr.25413)
164. Tabarin A, Navarranne A, Guerin J, Corcuff JB, Parmiex M & Roger P 1991 Use of ketaconazole in the treatment of Cushing's disease and ectopic ACTH syndrome. Clinical Endocrinology 34 63-69. (doi:10.1111/j.1365-2265.1991.tb01737.x)
165. Tanakol R, Alagol F, Azizlerli H, Sandalci O, Terzioglu T & Berker F 1996 Cyproheptadine treatment in Cushing's disease. Journal of Endocrinological Investigation 19 242-247. (doi:10.1007/BF03349875)
166. Thorn GW, Renold AE, Goldfien A, Nelson DH, Reddy WJ & Hertz R 1956 Inhibition of corticosteroid secretion by amphenone in a patient with adrenocortical carcinoma. New England Journal of Medicine 254 547-551. (doi:10.1056/NEJM195603222541202)
167. Tritos NA, Biller BM & Swearingen B 2011Management of Cushing disease. Nature Reviews. Endocrinology 7 279-289. (doi:10.1038/nrendo.2011.12)
168. Vale W, Rivier C, Brazeau P & Guillemin R 1974 Effects of somatostatin on the secretion by thyrotropin and prolactin. Endocrinology 95 968-977. (doi:10.1210/endo-95-4-968)
169. Van Cauter E & Refetoff S 1985 Evidence of two subtypes of Cushing's disease based on the analysis of episodic cortisol secretion. New England Journal of Medicine 312 1343-1349. (doi:10.1056/NEJM198505233122102)
170. Van der Lely AJ, Fockin K, Van der Mast RC & Lamberts SW 1991 Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU-486). Annals of Internal Medicine 114 143-144. (doi:10.7326/0003-4819-114-2-143)
171. Verhelst JA, Trainer FJ, Howlett TA, Perry L, Rees LH, Grossman AB, Wass AH & Besser GM 1991 Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clinical Endocrinology 35 169-178. (doi:10.1111/j.1365-2265.1991.tb03517.x)
172. Vignati F & Loli P 1996 Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism. Journal of Clinical Endocrinology and Metabolism 81 2885-2890. (doi:10.1210/jcem.81.8.8768846)
173. Vilar L, Naves LA, Azevedo MF, Arruda MJ, Arahata CM, Moura E, Silva L, Agra L, Pontes L, Montenegro L et al. 2010 Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitary 13 123-129. (doi:10.1007/s11102-009-0209-8)
174. Walsh LP, Kuratko CN & Stocco DM 2000 Econzale and miconazole inhibit steroidogenesis and disrupt steroidogenic acute regulatory (StAR) protein expression post-transcriptionally. Journal of Steroid Biochemistry and Molecular Biology 75 229-236. (doi:10.1016/S0960-0760(00) 00170-9)
175. Yin D, Kondo S, Takeuchi J & Morimura T 1994 Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine. FEBS Letters 339 73-75. (doi:10.1016/0014-5793(94)80387-0)
176. Young WF Jr & Thompson GB 2005 Laparoscopic adrenalectomy for patients who have Cushing's syndrome. Endocrinology and Metabolism Clinics of North America 34 489-499. (doi:10.1016/j.ecl.2005.01.006)